However, it will take more research to identify when and in which patients targeting Pin1 would be therapeutically beneficial because the effects of Pin1-based therapies may vary depending on the specific type of cancer or its history of development, as well as the specifics of a person’s neurodegenerative disease or neural biochemistry [321]. Here, PIN1 is linked to cancer.